Matching articles for "FluMist"
Issue 1740 · October 27, 2025 Free
Antiviral Drugs for Seasonal Influenza for 2025-2026

Influenza is generally a self-limited illness, but complications including pneumonia, respiratory failure, and death can occur, especially in persons at increased risk (see Table 1).

Med Lett Drugs Ther. 2025 Oct 27; 67(1740):169-74 doi:10.58347/tml.2025.1740a
Influenza is generally a self-limited illness, but complications including pneumonia, respiratory failure, and death can occur, especially in persons at increased risk (see Table 1).
Issue 1738 · September 29, 2025 Free
Influenza Vaccines for 2025-2026

Annual vaccination against influenza A and B viruses is recommended in the US for everyone ≥6 months old without a contraindication. Influenza vaccines available in the US for the 2025-2026 season are listed…

Med Lett Drugs Ther. 2025 Sep 29; 67(1738):153-8 doi:10.58347/tml.2025.1738a
Annual vaccination against influenza A and B viruses is recommended in the US for everyone ≥6 months old without a contraindication. Influenza vaccines available in the US for the 2025-2026 season are listed in Table 2.
Issue 1717 · December 9, 2024 Free
Antiviral Drugs for Seasonal Influenza for 2024-2025

Influenza is generally a self-limited illness, but pneumonia, respiratory failure, and death can occur, especially in persons at increased risk for influenza complications (see Table 1). Updated information on…

Med Lett Drugs Ther. 2024 Dec 9; 66(1717):193-8 doi:10.58347/tml.2024.1717a
Influenza is generally a self-limited illness, but pneumonia, respiratory failure, and death can occur, especially in persons at increased risk for influenza complications (see Table 1). Updated information on influenza activity and antiviral resistance is available from the CDC at cdc.gov/flu.
Issue 1717 · December 9, 2024 Free
Comparison Chart: Antiviral Drugs for Seasonal Influenza for 2024-2025 (online only)

View the Comparison Chart: Antiviral Drugs for Seasonal Influenza for 2024-2025

Med Lett Drugs Ther. 2024 Dec 9; 66(1717):e1-5 doi:10.58347/tml.2024.1717d
View the Comparison Chart: Antiviral Drugs for Seasonal Influenza for 2024-2025
Issue 1714 · October 28, 2024 Free
In Brief: FluMist Influenza Vaccine for Self-Administration

FluMist (AstraZeneca), the live-attenuated intranasal influenza vaccine that has been available for years for administration by a healthcare provider in nonpregnant persons 2-49 years old, has now been…

Med Lett Drugs Ther. 2024 Oct 28; 66(1714):174-5 doi:10.58347/tml.2024.1714c
FluMist (AstraZeneca), the live-attenuated intranasal influenza vaccine that has been available for years for administration by a healthcare provider in nonpregnant persons 2-49 years old, has now been approved by the FDA for self- or caregiver-administration. It is expected to be available for such use during the 2025-2026 influenza season. FluMist is only available through a healthcare provider this season. It will continue to be available for administration by a healthcare provider in the future
Issue 1711 · September 16, 2024 Free
Influenza Vaccine for 2024-2025

Annual vaccination in the US against influenza A and B viruses is recommended for everyone ≥6 months old without a contraindication. Influenza vaccines available in the US for the 2024-2025 season are listed…

Med Lett Drugs Ther. 2024 Sep 16; 66(1711):145-50 doi:10.58347/tml.2024.1711a
Annual vaccination in the US against influenza A and B viruses is recommended for everyone ≥6 months old without a contraindication. Influenza vaccines available in the US for the 2024-2025 season are listed in Table 2.
Issue 1687 · October 16, 2023 Free
Influenza Vaccine for 2023-2024

Annual vaccination in the US against influenza A and B viruses is recommended for everyone ≥6 months old without a contraindication. Influenza vaccines that are available in the US for the 2023-2024 season…

Med Lett Drugs Ther. 2023 Oct 16; 65(1687):161-6 doi:10.58347/tml.2023.1687a
Annual vaccination in the US against influenza A and B viruses is recommended for everyone ≥6 months old without a contraindication. Influenza vaccines that are available in the US for the 2023-2024 season are listed in Table 2.
Issue 1687 · October 16, 2023 Free
Influenza Vaccine for 2023-2024

Annual vaccination in the US against influenza A and B viruses is recommended for everyone ≥6 months old without a contraindication. Influenza vaccines that are available in the US for the 2023-2024 season…

Med Lett Drugs Ther. 2023 Oct 16; 65(1687):161-6 doi:10.58347/tml.2023.1687a
Annual vaccination in the US against influenza A and B viruses is recommended for everyone ≥6 months old without a contraindication. Influenza vaccines that are available in the US for the 2023-2024 season are listed in Table 2.
Issue 1664 · November 28, 2022 Free
Antiviral Drugs for Influenza for 2022-2023

Influenza is generally a self-limited illness, but complications such as pneumonia, respiratory failure, and death can occur, especially in patients at increased risk for influenza complications (see Table 1).…

Med Lett Drugs Ther. 2022 Nov 28; 64(1664):185-90
Influenza is generally a self-limited illness, but complications such as pneumonia, respiratory failure, and death can occur, especially in patients at increased risk for influenza complications (see Table 1). Antiviral drugs recommended for treatment and chemoprophylaxis of influenza this season are listed in Table 2. Updated information on influenza activity and antiviral resistance is available from the CDC at www.cdc.gov/flu. None of the drugs that are FDA-approved for treatment of influenza have clinically relevant antiviral activity against SARS-CoV-2.
Issue 1664 · November 28, 2022 Free
Comparison Chart: Antiviral Drugs for Influenza for 2022-2023 (online only)

View the Comparison Chart: Antiviral Drugs for Influenza for 2022-2023

Med Lett Drugs Ther. 2022 Nov 28; 64(1664):e1-5
View the Comparison Chart: Antiviral Drugs for Influenza for 2022-2023
Issue 1660 · October 3, 2022 Free
Influenza Vaccine for 2022-2023

Annual vaccination in the US against influenza A and B viruses is recommended for everyone ≥6 months old without a contraindication. Influenza vaccines that are available in the US for the 2022-2023 season…

Med Lett Drugs Ther. 2022 Oct 3; 64(1660):153-7
Annual vaccination in the US against influenza A and B viruses is recommended for everyone ≥6 months old without a contraindication. Influenza vaccines that are available in the US for the 2022-2023 season are listed in Table 2.
Issue 1641 · January 10, 2022 Free
Antiviral Drugs for Influenza for 2021-2022

Influenza is generally a self-limited illness, but complications such as pneumonia, respiratory failure, and death can occur, especially in patients at higher risk for complications (see Table 1). Antiviral…

Med Lett Drugs Ther. 2022 Jan 10; 64(1641):2-7
Influenza is generally a self-limited illness, but complications such as pneumonia, respiratory failure, and death can occur, especially in patients at higher risk for complications (see Table 1). Antiviral drugs recommended for treatment and chemoprophylaxis of influenza this season are listed in Table 2. Updated information on influenza activity and antiviral resistance is available from the CDC at www.cdc.gov/flu.
Issue 1641 · January 10, 2022 Free
Comparison Chart: Antiviral Drugs for Influenza for 2021-2022 (online only)

View the Comparison Chart: Antiviral Drugs for Influenza for 2021-2022

Med Lett Drugs Ther. 2022 Jan 10; 64(1641):e1-5
View the Comparison Chart: Antiviral Drugs for Influenza for 2021-2022
Issue 1634 · October 4, 2021 Free
Influenza Vaccine for 2021-2022

Annual vaccination against influenza A and B viruses is recommended for everyone ≥6 months old without a contraindication.1 Available influenza vaccines for the 2021-2022 season are listed in Table 2.

Med Lett Drugs Ther. 2021 Oct 4; 63(1634):153-7
Annual vaccination against influenza A and B viruses is recommended for everyone ≥6 months old without a contraindication.1 Available influenza vaccines for the 2021-2022 season are listed in Table 2.
Issue 1610 · November 2, 2020
Antiviral Drugs for Influenza for 2020-2021

Influenza is generally a self-limited illness, but complications such as pneumonia, respiratory failure, and death can occur, especially in patients at increased risk for influenza complications (see Table 1).…

Med Lett Drugs Ther. 2020 Nov 2; 62(1610):169-73
Influenza is generally a self-limited illness, but complications such as pneumonia, respiratory failure, and death can occur, especially in patients at increased risk for influenza complications (see Table 1). Antiviral drugs recommended for treatment and chemoprophylaxis of influenza this season are listed in Table 2. Updated information on influenza activity and antiviral resistance is available from the CDC at www.cdc.gov/flu.
Issue 1607 · September 21, 2020
Influenza Vaccine for 2020-2021

Annual vaccination against influenza A and B viruses is recommended for everyone ≥6 months old without a contraindication. Vaccination of all eligible persons can reduce the prevalence of influenza illness…

Med Lett Drugs Ther. 2020 Sep 21; 62(1607):145-50
Annual vaccination against influenza A and B viruses is recommended for everyone ≥6 months old without a contraindication. Vaccination of all eligible persons can reduce the prevalence of influenza illness and symptoms that might be confused with those of COVID-19. Available vaccines and recommendations for specific patient populations for the 2020-2021 season are listed in Tables 2 and 3. Lower rates of influenza illness have been observed this season in the Southern Hemisphere, probably because of masking, social distancing, school closures, and travel restrictions.
Issue 1589 · January 13, 2020
Antiviral Drugs for Influenza

Influenza is generally a self-limited illness, but pneumonia, respiratory failure, and death can occur. FDA-approved antiviral drugs for influenza are listed in Table 2. The neuraminidase inhibitors…

Med Lett Drugs Ther. 2020 Jan 13; 62(1589):1-4
Influenza is generally a self-limited illness, but pneumonia, respiratory failure, and death can occur. FDA-approved antiviral drugs for influenza are listed in Table 2. The neuraminidase inhibitors oseltamivir ( Tamiflu , and generics), which is taken orally, and zanamivir (Relenza) , which is inhaled, are approved for prophylaxis and treatment of acute uncomplicated influenza. The IV neuraminidase inhibitor peramivir (Rapivab) and the oral polymerase acidic (PA) endonuclease inhibitor baloxavir marboxil (Xofluza) are approved only for treatment. All of these drugs are active against both influenza A and influenza B viruses. Updated information on influenza activity and antiviral resistance is available from the CDC at www.cdc.gov/flu.
Issue 1583 · October 21, 2019
Influenza Vaccine for 2019-2020

Annual vaccination against influenza A and B viruses is recommended for everyone ≥6 months old without a contraindication. Available vaccines and recommendations for specific patient populations for the…

Med Lett Drugs Ther. 2019 Oct 21; 61(1583):161-6
Annual vaccination against influenza A and B viruses is recommended for everyone ≥6 months old without a contraindication. Available vaccines and recommendations for specific patient populations for the 2019-2020 season are listed in Tables 2 and 3.
Issue 1563 · January 14, 2019
Antiviral Drugs for Treatment and Prophylaxis of Seasonal Influenza

Antiviral drugs can be used for treatment and prophylaxis of seasonal influenza (see Table 1). Frequently updated information on influenza activity, influenza testing, and antiviral resistance is available…

Med Lett Drugs Ther. 2019 Jan 14; 61(1563):1-4
Antiviral drugs can be used for treatment and prophylaxis of seasonal influenza (see Table 1). Frequently updated information on influenza activity, influenza testing, and antiviral resistance is available from the CDC at www.cdc.gov/flu.
Issue 1558 · October 22, 2018
Influenza Vaccine for 2018-2019

Routine annual vaccination against influenza A and B viruses is recommended for everyone ≥6 months old. Recommendations for the current season for specific patient populations are listed in Tables 2 and 4.

Med Lett Drugs Ther. 2018 Oct 22; 60(1558):169-73
Routine annual vaccination against influenza A and B viruses is recommended for everyone ≥6 months old. Recommendations for the current season for specific patient populations are listed in Tables 2 and 4.
Issue 1537 · January 1, 2018
Antiviral Drugs for Seasonal Influenza 2017-2018

Antiviral drugs can be used for treatment and prophylaxis of influenza. Frequently updated information on influenza activity, testing for influenza, and antiviral resistance is available from the CDC at…

Med Lett Drugs Ther. 2018 Jan 1; 60(1537):1-4
Antiviral drugs can be used for treatment and prophylaxis of influenza. Frequently updated information on influenza activity, testing for influenza, and antiviral resistance is available from the CDC at www.cdc.gov/flu.
Issue 1531 · October 9, 2017
Influenza Vaccine for 2017-2018

Routine annual vaccination against influenza A and B viruses is recommended for everyone ≥6 months old without a specific contraindication.

Med Lett Drugs Ther. 2017 Oct 9; 59(1531):163-6
Routine annual vaccination against influenza A and B viruses is recommended for everyone ≥6 months old without a specific contraindication.
Issue 1505 · October 10, 2016
Influenza Vaccine for 2016-2017

Annual vaccination against influenza A and B viruses is recommended for everyone ≥6 months old without a specific contraindication.

Med Lett Drugs Ther. 2016 Oct 10; 58(1505):127-30
Annual vaccination against influenza A and B viruses is recommended for everyone ≥6 months old without a specific contraindication.
Issue 1477 · September 14, 2015
Influenza Vaccine for 2015-2016

Annual vaccination against influenza A and B viruses is recommended for everyone ≥6 months old without a specific contraindication.

Med Lett Drugs Ther. 2015 Sep 14; 57(1477):125-7
Annual vaccination against influenza A and B viruses is recommended for everyone ≥6 months old without a specific contraindication.
Issue 1461 · February 2, 2015
Peramivir (Rapivab): An IV Neuraminidase Inhibitor for Treatment of Influenza

The FDA has approved peramivir ( Rapivab – BioCryst), an IV neuraminidase inhibitor administered as a single dose, for treatment of acute uncomplicated influenza in patients ≥18 years old who have had…

Med Lett Drugs Ther. 2015 Feb 2; 57(1461):17-9
The FDA has approved peramivir ( Rapivab – BioCryst), an IV neuraminidase inhibitor administered as a single dose, for treatment of acute uncomplicated influenza in patients ≥18 years old who have had symptoms for no more than 2 days. Peramivir was available temporarily in the US during the 2009-2010 influenza season under an emergency use authorization for treatment of hospitalized patients. It has been available in some Asian countries since 2010. Peramivir is the third neuraminidase inhibitor to be approved in the US. Oseltamivir (Tamiflu) , which is taken orally, and zanamivir (Relenza) , which is inhaled, are approved for prophylaxis and treatment of influenza in children and adults.
Issue 1457 · December 8, 2014
Antiviral Drugs for Seasonal Influenza 2014-2015

Antiviral drugs can be used for treatment of influenza and as an adjunct to influenza vaccination for prophylaxis. Frequently updated information on influenza activity and antiviral resistance is available…

Med Lett Drugs Ther. 2014 Dec 8; 56(1457):121-2
Antiviral drugs can be used for treatment of influenza and as an adjunct to influenza vaccination for prophylaxis. Frequently updated information on influenza activity and antiviral resistance is available from the CDC at www.cdc.gov/flu.
Issue 1453 · October 13, 2014
Influenza Vaccine for 2014-2015

Annual vaccination against influenza A and B viruses has been shown to decrease influenza illness and its complications.

Med Lett Drugs Ther. 2014 Oct 13; 56(1453):97-9
Annual vaccination against influenza A and B viruses has been shown to decrease influenza illness and its complications.
Issue 142 · June 1, 2014
Adult Immunization

Vaccines recommended for adults residing in the US are reviewed here. Vaccines for travel have been reviewed separately. Eight vaccines are currently recommended by the US Advisory Committee on Immunization…

Treat Guidel Med Lett. 2014 Jun; 12(142):39-48
Vaccines recommended for adults residing in the US are reviewed here. Vaccines for travel have been reviewed separately. Eight vaccines are currently recommended by the US Advisory Committee on Immunization Practices (ACIP) for routine use in adults at various ages...
Issue 1434 · January 20, 2014
Antiviral Drugs for Influenza 2013-2014

Antiviral drugs can be used for treatment of influenza and as an adjunct to influenza vaccination for prophylaxis. Frequently updated information on antiviral resistance is available at www.cdc.gov .

Med Lett Drugs Ther. 2014 Jan 20; 56(1434):6-8
Antiviral drugs can be used for treatment of influenza and as an adjunct to influenza vaccination for prophylaxis. Frequently updated information on antiviral resistance is available at www.cdc.gov .
Issue 1425 · September 16, 2013
Influenza Vaccine for 2013-2014

Annual vaccination against influenza A and B viruses has been shown to decrease influenza illness and its complications. Several new vaccines are available for the current season.

Med Lett Drugs Ther. 2013 Sep 16; 55(1425):73-5
Annual vaccination against influenza A and B viruses has been shown to decrease influenza illness and its complications. Several new vaccines are available for the current season.
Issue 1405 · December 10, 2012
Antiviral Drugs for Influenza 2012-2013

Antiviral drugs can be used as an adjunct to vaccination for prophylaxis and treatment of influenza. In recent years, the susceptibility of circulating influenza virus strains has evolved rapidly and treatment…

Med Lett Drugs Ther. 2012 Dec 10; 54(1405):97-8
Antiviral drugs can be used as an adjunct to vaccination for prophylaxis and treatment of influenza. In recent years, the susceptibility of circulating influenza virus strains has evolved rapidly and treatment recommendations have changed during the influenza season. Frequently updated information on antiviral resistance is available at www.cdc.gov/flu/professionals/antivirals.
Issue 1400 · October 1, 2012
Influenza Vaccine for 2012-2013

Annual vaccination against influenza A and B viruses is the most effective method of preventing influenza and has been shown to decrease influenza illness and its complications. A new vaccine is available for…

Med Lett Drugs Ther. 2012 Oct 1; 54(1400):77-8
Annual vaccination against influenza A and B viruses is the most effective method of preventing influenza and has been shown to decrease influenza illness and its complications. A new vaccine is available for the current season. Chemoprophylaxis and treatment of influenza was discussed in an earlier issue.
Issue 112 · December 1, 2011
Adult Immunizations

Vaccines recommended for routine use in US adults are reviewed here. Vaccines for travel have been reviewed separately.

Treat Guidel Med Lett. 2011 Dec; 9(112):75-82
Vaccines recommended for routine use in US adults are reviewed here. Vaccines for travel have been reviewed separately.
Issue 1375 · October 17, 2011
Influenza Vaccine for 2011-2012

Annual vaccination against influenza A and B viruses is the most effective method of preventing influenza and has been shown to decrease influenza illness and complications. For the current season, a new…

Med Lett Drugs Ther. 2011 Oct 17; 53(1375):81-3
Annual vaccination against influenza A and B viruses is the most effective method of preventing influenza and has been shown to decrease influenza illness and complications. For the current season, a new inactivated intradermal vaccine (Fluzone Intradermal) has been FDA-approved for use in adults 18-64 years old. An upcoming issue will review chemoprophylaxis and treatment of influenza.
Issue 1348 · October 4, 2010
Seasonal Trivalent Influenza Vaccine for 2010-2011

Annual vaccination against influenza A and B viruses is the most effective method of preventing influenza. An upcoming issue of The Medical Letter will review drugs for chemoprophylaxis and treatment of…

Med Lett Drugs Ther. 2010 Oct 4; 52(1348):77-9
Annual vaccination against influenza A and B viruses is the most effective method of preventing influenza. An upcoming issue of The Medical Letter will review drugs for chemoprophylaxis and treatment of influenza.
Issue 1325 · November 16, 2009
Antiviral Drugs for Influenza

Currently circulating influenza virus is almost universally pandemic 2009 influenza A H1N1, but seasonal influenza strains could also appear soon. Antiviral drugs are an important adjunct to influenza…

Med Lett Drugs Ther. 2009 Nov 16; 51(1325):89-92
Currently circulating influenza virus is almost universally pandemic 2009 influenza A H1N1, but seasonal influenza strains could also appear soon. Antiviral drugs are an important adjunct to influenza vaccination for treatment and chemoprophylaxis of both pandemic and seasonal influenza. They may, however, interfere with the efficacy of FluMist , the live-attenuated intranasal vaccine, if they are administered within 48 hours before or <2 weeks after FluMist administration. Inactivated vaccines are not affected by antiviral drug therapy.
Issue 1321 · September 21, 2009
Seasonal Trivalent Influenza Vaccine for 2009-2010

Two separate influenza vaccines will be available this season: the usual seasonal trivalent vaccine and a monovalent vaccine (not yet licensed by the FDA) directed at the novel H1N1 virus currently causing…

Med Lett Drugs Ther. 2009 Sep 21; 51(1321):73-4
Two separate influenza vaccines will be available this season: the usual seasonal trivalent vaccine and a monovalent vaccine (not yet licensed by the FDA) directed at the novel H1N1 virus currently causing pandemic infection. The next issue of the Medical Letter will review the pandemic H1N1 vaccine.
Issue 80 · April 1, 2009
Adult Immunization

Although immunization programs have produced high vaccination rates in US infants and children, similar successes have not been achieved in adults. Vaccines recommended for routine use in adults are reviewed…

Treat Guidel Med Lett. 2009 Apr; 7(80):27-36
Although immunization programs have produced high vaccination rates in US infants and children, similar successes have not been achieved in adults. Vaccines recommended for routine use in adults are reviewed here. Vaccines for travel are reviewed separately.
Issue 1296 · October 6, 2008
Influenza Vaccine 2008-2009

Annual immunization against influenza A and B is the most effective method of preventing infection and has been shown to reduce influenza complications. Changes this year include a vaccine with three new…

Med Lett Drugs Ther. 2008 Oct 6; 50(1296):77-8
Annual immunization against influenza A and B is the most effective method of preventing infection and has been shown to reduce influenza complications. Changes this year include a vaccine with three new influenza antigens and expanded age criteria to include all children 6 months to 18 years of age. An upcoming issue of The Medical Letter will review drugs for prophylaxis and treatment of influenza.
Issue 1271 · October 8, 2007
Influenza Vaccine 2007-2008

Annual immunization against influenza A and B is the most effective method of preventing infection and has been shown to reduce associated complications.

Med Lett Drugs Ther. 2007 Oct 8; 49(1271):81-3
Annual immunization against influenza A and B is the most effective method of preventing infection and has been shown to reduce associated complications.
Issue 1245 · October 9, 2006
Influenza Vaccine 2006-2007

Annual immunization against influenza A and B is the most effective method of preventing infection and has been shown to reduce associated complications.

Med Lett Drugs Ther. 2006 Oct 9; 48(1245):81-3
Annual immunization against influenza A and B is the most effective method of preventing infection and has been shown to reduce associated complications.
Issue 47 · July 1, 2006
Adult Immunization

Although immunization programs have produced high vaccination rates in US infants and children, similar successes have not been achieved in adults. Vaccines recommended for routine use in adults are reviewed…

Treat Guidel Med Lett. 2006 Jul; 4(47):47-54
Although immunization programs have produced high vaccination rates in US infants and children, similar successes have not been achieved in adults. Vaccines recommended for routine use in adults are reviewed here. Immunizations for travel were reviewed in a recent issue.
Issue 1222 · November 21, 2005
Antiviral Drugs for Prophylaxis and Treatment of Influenza

Antiviral prophylaxis is indicated for influenza exposures that occur before (or less than 2 weeks after) vaccination with inactivated vaccine, or in years when circulating strains differ from those included…

Med Lett Drugs Ther. 2005 Nov 21; 47(1222):93-5
Antiviral prophylaxis is indicated for influenza exposures that occur before (or less than 2 weeks after) vaccination with inactivated vaccine, or in years when circulating strains differ from those included in the vaccine. Antiviral drugs can also be used for treatment of patients who develop symptoms of influenza, regardless of vaccination status. Please see Update: Influenza Resistance to Amantadine and Rimantadine
Issue 1220 · October 24, 2005
Influenza Vaccine 2005-2006

Annual immunization against influenza A and B is the most effective method of preventing infection and has been shown to reduce associated complications. A future issue of The Medical Letter will review drug…

Med Lett Drugs Ther. 2005 Oct 24; 47(1220):85-7
Annual immunization against influenza A and B is the most effective method of preventing infection and has been shown to reduce associated complications. A future issue of The Medical Letter will review drug prophylaxis and treatment of influenza.
Issue 1194 · October 25, 2004
Antiviral Drugs for Prophylaxis and Treatment of Influenza

Due to the unanticipated shortage in the US supply of inactivated influenza vaccine, many persons who normally would have received the vaccine will be unable to get it this year. Antiviral drugs can be used…

Med Lett Drugs Ther. 2004 Oct 25; 46(1194):85-7
Due to the unanticipated shortage in the US supply of inactivated influenza vaccine, many persons who normally would have received the vaccine will be unable to get it this year. Antiviral drugs can be used for prophylaxis of unvaccinated persons who are exposed to influenza, and for treatment of both vaccinated and unvaccinated patients who develop symptoms of the disease.
Issue 1193 · October 11, 2004
Influenza Vaccine 2004-2005

Last year influenza season began in October, peaked in December (both much earlier than usual), and was associated with severe disease, particularly in children. Much of the illness was due to a circulating…

Med Lett Drugs Ther. 2004 Oct 11; 46(1193):83-4
Last year influenza season began in October, peaked in December (both much earlier than usual), and was associated with severe disease, particularly in children. Much of the illness was due to a circulating influenza A H3N2 strain (Fujian type) that had drifted antigenically from the H3N2 strain in the vaccine. The vaccine for the 2004-05 influenza season includes A/Wyoming/3/2003 (H3N2), which is antigenically equivalent to the Fujian strain, A/New Caledonia/20/99 (H1N1), which is unchanged, and a new B strain, either B/Jiangsu/10/2003 or B/Jilin/20/2003, which are both antigenically equivalent to B/Shanghai/361/2002.
Issue 1176 · February 16, 2004 Free
FluMist: An Intranasal Live Influenza Vaccine - Addendum

Addendum: FluMist Storage: The storage requirements for FluMist, the intranasal live-attenuated influenza vaccine (Medical Letter 2003; 45:65) have changed. New data have shown that frost-free freezers are…

Med Lett Drugs Ther. 2004 Feb 16; 46(1176):16
Addendum: FluMist Storage: The storage requirements for FluMist, the intranasal live-attenuated influenza vaccine (Medical Letter 2003; 45:65) have changed. New data have shown that frost-free freezers are appropriate for storage for at least 3 months, without need for a freezer-box insert.
Issue 1166 · September 29, 2003
Influenza Prevention 2003-2004

Unlike the last few years there is no early-season shortage of influenza vaccine. Immunization programs for all recommended individuals can proceed. There are 2 new influenza vaccine formulations available…

Med Lett Drugs Ther. 2003 Sep 29; 45(1166):78-80
Unlike the last few years there is no early-season shortage of influenza vaccine. Immunization programs for all recommended individuals can proceed. There are 2 new influenza vaccine formulations available this year, FluMist , an intranasal vaccine and Fluzone , a pediatric formulation. Timing, indications, adverse effects, dosage and cost of the vaccines is discussed. The drugs that can be used for prophylaxis of influenza are also reviewed.
Issue 1163 · August 19, 2003
FluMist: An Intranasal Live Influenza Vaccine

FluMist (MedImmune), the first live-attenuated and first intranasally administered influenza vaccine, has been approved by the FDA to prevent influenza in healthy people 5-49 years old. Given as a nasal spray,…

Med Lett Drugs Ther. 2003 Aug 19; 45(1163):65-6
FluMist (MedImmune), the first live-attenuated and first intranasally administered influenza vaccine, has been approved by the FDA to prevent influenza in healthy people 5-49 years old. Given as a nasal spray, it stimulates immunity by viral replication in the upper respiratory tract. This vaccine apparently will be advertised directly to the public as a "needle-free" alternative to intramuscular influenza vaccine.